Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice

Hepatology Research

Volumn 45, Issue 3, 2015, Pages 305-314

  Quillin, Ralph C ^a   Wilson, Gregory C ^a   Nojima, Hiroyuki ^a   Freeman, Christopher M ^a   Wang, Jiang ^a   Schuster, Rebecca M ^a   Blanchard, John A ^a   Edwards, Michael J ^a   Gandhi, Chandrashekhar R ^a,b,c   Gulbins, Erich ^a   Lentsch, Alex B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c Veteran's Administration   (United States)

Author keywords

Liver fibrosis; Non alcoholic steatohepatitis; Stellate cells

Indexed keywords

ACIDIC SPHINGOMYELINASE; ALPHA SMOOTH MUSCLE ACTIN; AMITRIPTYLINE; CARBON TETRACHLORIDE; COLLAGEN; DRINKING WATER; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BB; SPHINGOMYELIN PHOSPHODIESTERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; FIBROGENESIS; GENE EXPRESSION; IN VITRO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; STELLATE CELL;

EID: 84924053483     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12352     Document Type: Article

References (39)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
2. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
3. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-1019.
4. Kim WR, Stock PG, Smith JM etal. OPTN/SRTR 2011 annual data report: liver. Am J Transplant 2013; 13 (Suppl 1): 73-102.
5. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
6. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2008; 2: 803-816.
7. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep 2013; 1: 209-214.
8. Kornhuber J, Tripal P, Reichel M etal. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010; 26: 9-20.
9. Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta 2005; 1746: 284-294.
10. Shea BS, Tager AM. Sphingolipid regulation of tissue fibrosis. Open Rheumatol J 2012; 6: 123-129.
11. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150.
12. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73: 321-354.
13. Rivera R, Chun J. Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol 2008; 160: 25-46.
14. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 2012; 23: 365-371.
15. Smith EL, Schuchman EH. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J 2008; 22: 3419-3431.
16. Henry B, Moller C, Dimanche-Boitrel MT, Gulbins E, Becker KA. Targeting the ceramide system in cancer. Cancer Lett 2013; 332: 286-294.
17. Kornhuber J, Tripal P, Gulbins E, Muehlbacher M. Functional inhibitors of acid sphingomyelinase (FIASMAs). Handb Exp Pharmacol 2013; 215: 169-186.
18. Becker KA, Tummler B, Gulbins E, Grassme H. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem Biophys Res Commun 2010; 403: 368-374.
19. Moles A, Tarrats N, Morales A etal. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol 2010; 177: 1214-1224.
20. Nahrlich L, Mainz JG, Adams C etal. Therapy of CF-patients with amitriptyline and placebo - a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem 2013; 31: 505-512.
21. Lang PA, Schenck M, Nicolay JP etal. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13: 164-170.
22. Domenicali M, Caraceni P, Giannone F etal. A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol 2009; 51: 991-999.
23. Teichgraber V, Ulrich M, Endlich N etal. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14: 382-391.
24. Brand V, Koka S, Lang C etal. Influence of amitriptyline on eryptosis, parasitemia and survival of Plasmodium berghei-infected mice. Cell Physiol Biochem 2008; 22: 405-412.
25. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
26. Sumpter TL, Dangi A, Matta BM etal. Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO. J Immunol 2012; 189: 3848-3858.
27. Dangi A, Sumpter TL, Kimura S etal. Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. J Immunol 2012; 188: 3667-3677.
28. Ziobro R, Henry B, Edwards MJ, Lentsch AB, Gulbins E. Ceramide mediates lung fibrosis in cystic fibrosis. Biochem Biophys Res Commun 2013; 434: 705-709.
29. de Meijer VE, Sverdlov DY, Popov Y etal. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS ONE 2010; 5: e11256.
30. Dumont AE, Amorosi E, Stahl WM. Significance of splenomegaly in patients with hepatic cirrhosis and bleeding esophageal varices. Ann Surg 1970; 171: 522-526.
31. Kinnman N, Goria O, Wendum D etal. Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest 2001; 81: 1709-1716.
32. Chen SW, Chen YX, Zhang XR, Qian H, Chen WZ, Xie WF. Targeted inhibition of platelet-derived growth factor receptor-beta subunit in hepatic stellate cells ameliorates hepatic fibrosis in rats. Gene Ther 2008; 15: 1424-1435.
33. Liu P, Anderson RG. Compartmentalized production of ceramide at the cell surface. J Biol Chem 1995; 270: 27179-27185.
34. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998; 275: L843-851.
35. Zundel W, Swiersz LM, Giaccia A. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol 2000; 20: 1507-1514.
36. Liu P, Ying Y, Ko YG, Anderson RG. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem 1996; 271: 10299-10303.
37. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001; 276: 6727-6738.
38. Furukawa F, Matsuzaki K, Mori S etal. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003; 38: 879-889.
39. Inagaki Y, Mamura M, Kanamaru Y etal. Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 2001; 187: 117-123.